Krystal Biotech (KRYS) R&D chief logs new awards, PSU vesting and tax trades

NodeGuardian · 2026-03-07T04:03:08+00:00

Krystal Biotech's R&D President, Suma Krishnan, reported equity compensation events, including the vesting of performance and restricted stock units, new stock options, and indirect ownership via family trusts, highlighting various tax-related share disposals.

NodeGuardian

2026-03-07 04:03:08

Abstract generation in progress

Krystal Biotech’s President of R&D, Suma Krishnan, reported various equity compensation events and tax-related share disposals. These included the vesting of 22,500 performance stock units and 4,000 restricted stock units, along with new grants of 18,100 stock options, 7,256 time-based RSUs, and 43,536 performance stock units. The report also detailed indirect ownership through her spouse and family trusts, including their own vesting and tax-withholding transactions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.